Core Viewpoint - The legal opinion letter from Anhui Tianhe Law Firm confirms that Tongling Jieya Biotechnology Co., Ltd. has complied with relevant laws and regulations regarding its 2025 Restricted Stock Incentive Plan, including necessary approvals and authorizations for the initial grant of restricted stock [1][3][4]. Summary by Sections Approval and Authorization of Grant - The Compensation and Assessment Committee and the Board of Directors have approved the draft of the 2025 Restricted Stock Incentive Plan and related proposals [3][4]. - The company has fulfilled necessary approval and authorization procedures for the grant of restricted stock [4][5]. Basic Information of the Grant - The initial grant date for the restricted stock is set for September 2, 2025, with a total of 1,498,000 shares to be granted to 10 incentive recipients [4][5]. - The grant date complies with the regulations, being within 60 days of the shareholders' meeting approval [5]. Recipients of the Grant - The distribution of the granted shares among the recipients is as follows: - Directors and senior management will receive 38.46% of the total shares, while other incentivized personnel will receive 43.85% [6]. - The total number of shares granted to the 10 recipients is 1,498,000, with a reserved portion of 322,000 shares [6]. Conditions for Granting - Recipients must meet specific conditions to be eligible for the restricted stock, including no negative audit opinions in the last fiscal year and no legal restrictions on participating in stock incentives [7][8]. - The company has confirmed that all conditions for granting the restricted stock have been met [8]. Conclusion - The legal opinion concludes that all necessary approvals, grant dates, recipient qualifications, and conditions have been satisfied, ensuring compliance with the relevant regulations [8].
洁雅股份: 安徽天禾律师事务所关于铜陵洁雅生物科技股份有限公司2025年限制性股票激励计划首次授予事项之法律意见书